ATE234079T1 - Pharmazeutische dosierungsform mit mehrfachen enterischen polymer-überzügenzur abgabe im kolon - Google Patents

Pharmazeutische dosierungsform mit mehrfachen enterischen polymer-überzügenzur abgabe im kolon

Info

Publication number
ATE234079T1
ATE234079T1 AT97910953T AT97910953T ATE234079T1 AT E234079 T1 ATE234079 T1 AT E234079T1 AT 97910953 T AT97910953 T AT 97910953T AT 97910953 T AT97910953 T AT 97910953T AT E234079 T1 ATE234079 T1 AT E234079T1
Authority
AT
Austria
Prior art keywords
enteric polymer
coating layer
colon
dosage form
tablet
Prior art date
Application number
AT97910953T
Other languages
English (en)
Inventor
Gary Robert Kelm
Koji Kondo
Akio Nakajima
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of ATE234079T1 publication Critical patent/ATE234079T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97910953T 1996-10-11 1997-10-10 Pharmazeutische dosierungsform mit mehrfachen enterischen polymer-überzügenzur abgabe im kolon ATE234079T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/728,946 US5914132A (en) 1993-02-26 1996-10-11 Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
PCT/US1997/018564 WO1998016206A1 (en) 1996-10-11 1997-10-10 Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery

Publications (1)

Publication Number Publication Date
ATE234079T1 true ATE234079T1 (de) 2003-03-15

Family

ID=24928914

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97910953T ATE234079T1 (de) 1996-10-11 1997-10-10 Pharmazeutische dosierungsform mit mehrfachen enterischen polymer-überzügenzur abgabe im kolon

Country Status (9)

Country Link
US (1) US5914132A (de)
EP (1) EP0932396B1 (de)
JP (1) JP4276299B2 (de)
CN (1) CN1101675C (de)
AT (1) ATE234079T1 (de)
BR (1) BR9712292A (de)
CA (1) CA2268175C (de)
DE (1) DE69719774T2 (de)
WO (1) WO1998016206A1 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6884792B2 (en) * 1999-01-08 2005-04-26 Marvin B. Bacaner Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
CA2358459C (en) 1999-01-08 2011-05-24 Marvin B. Bacaner Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2001023000A1 (fr) * 1999-09-30 2001-04-05 Otsuka Pharmaceutical Company, Limited Preparations d'enrobage solubles dans le tube digestif inferieur
US6420473B1 (en) 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
PL202884B1 (pl) * 2000-02-10 2009-07-31 Bpsi Holdings Nietoksyczna, jadalna, powłokotwórcza kompozycja proszkowa zabezpieczająca przed działaniem soku żołądkowego, sposób sporządzania wodnego układu dyspersyjnego oraz sposób powlekania substratów
CA2415957C (en) * 2000-06-23 2010-08-10 Bioprojet Dry powder formulation comprising racecadotril
IT1318625B1 (it) 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6887492B2 (en) 2000-12-14 2005-05-03 Leiner Health Services Corp. Magnesium plus interactive agent delivery
EP1390032A4 (de) * 2001-05-11 2004-12-29 Marvin B Bacaner Neue, mit erleichternden anionen gekuppelte quaternäre ammoniumzusammensetzungen und ihre verwendung in kits sowie ihre verwendung bei der prävention und behandlung bestimmter erkrankungen
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP2112920B1 (de) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Protonenpumpeninhibitoren enthaltende kapseln, die verschieden aufgebaute untereinheiten zur verzögerten wirkstofffreisetzung enthalten
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070196484A1 (en) * 2004-03-10 2007-08-23 Kaoru Wada Poorly water-soluble drug-containing solid formulation
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20060147394A1 (en) † 2004-12-30 2006-07-06 Ramachandra Shastry Tooth whitening composition containing cross-linked polymer-peroxides
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
EP2392258B1 (de) * 2005-04-28 2014-10-08 Proteus Digital Health, Inc. Pharma-Informatiksystem
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US7964215B1 (en) * 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20070292510A1 (en) * 2006-06-19 2007-12-20 Hugh Huang Enteric coated particles containing an active ingredient
WO2008122965A2 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090136650A1 (en) * 2007-09-18 2009-05-28 Viva Pharmaceuticals Inc. Enteric coatings for orally ingestible compositions
US20090074944A1 (en) * 2007-09-18 2009-03-19 Viva Pharmaceuticals Inc. Enteric coatings for orally ingestible compositions
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
AR071706A1 (es) * 2008-05-15 2010-07-07 Otsuka Pharma Co Ltd Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
SG10201810784SA (en) 2009-04-28 2018-12-28 Proteus Digital Health Inc Highly Reliable Ingestible Event Markers And Methods For Using The Same
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
EP2464341B1 (de) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunmodulatorische zusammensetzungen mit einer polymermatrix und einer ölphase
SG10201502720VA (en) 2010-04-07 2015-05-28 Proteus Digital Health Inc Miniature ingestible device
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
EP2642983A4 (de) 2010-11-22 2014-03-12 Proteus Digital Health Inc Einnehmbare vorrichtung mit einem pharmazeutischen produkt
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
PL2736497T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
CN102319218B (zh) * 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
JP6203816B2 (ja) * 2012-03-29 2017-09-27 セラバイオーム，エルエルシー 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
ES2655622T3 (es) * 2012-04-30 2018-02-20 Tillotts Pharma Ag Una formulación de fármaco de liberación retardada
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
KR102008417B1 (ko) * 2012-12-04 2019-08-08 롯데정밀화학 주식회사 적층 필름 및 필름 적층방법
TWI659994B (zh) 2013-01-29 2019-05-21 美商普羅托斯數位健康公司 高度可膨脹之聚合型薄膜及包含彼之組成物
CA2901166C (en) 2013-02-22 2020-03-24 Zeria Pharmaceutical Co., Ltd. Enteric coated tablet
US9763887B2 (en) 2013-03-15 2017-09-19 Allergan Pharmaceuticals International Limited Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
JP5941240B2 (ja) 2013-03-15 2016-06-29 プロテウス デジタル ヘルス， インコーポレイテッド 金属検出器装置、システム、および方法
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
CN105392475A (zh) * 2013-07-24 2016-03-09 诺和诺德股份有限公司 包含片剂核和阴离子共聚物涂层的用于口服胰岛素给药的药学组合物
CN104337773B (zh) * 2013-08-06 2018-11-30 天士力医药集团股份有限公司 穿心莲内酯在制备炎症性肠病的药物中的应用、穿心莲内酯肠溶靶向微丸及其制备方法
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
NZ717159A (en) * 2013-10-29 2019-06-28 Tillotts Pharma Ag A delayed release drug formulation
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
GB201319792D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
CN106176619B (zh) * 2014-08-06 2020-10-16 天士力医药集团股份有限公司 一种穿心莲内酯肠溶微丸定位制剂
HUE053624T2 (hu) 2014-11-07 2021-07-28 Sublimity Therapeutics Ltd Ciklosporint tartalmazó készítmények
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
CN109562137A (zh) 2015-09-01 2019-04-02 第波生物公司 用于治疗与异常炎性反应有关的病况的方法和组合物
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
US20170296476A1 (en) * 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms
BR112019000861B1 (pt) 2016-07-22 2020-10-27 Proteus Digital Health, Inc dispositivo eletrônico
CA3041041A1 (en) 2016-10-26 2018-05-03 Proteus Digital Health, Inc. Methods for manufacturing capsules with ingestible event markers
ES2994844T3 (en) * 2018-12-07 2025-02-03 Tillotts Pharma Ag Colonic drug delivery formulation
ES3002632T3 (en) 2018-12-07 2025-03-07 Tillotts Pharma Ag Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
MX2022001865A (es) 2019-08-12 2022-03-11 Massachusetts Inst Technology Articulos y metodos para la administracion de agentes terapeuticos.
US20230102999A1 (en) 2020-01-10 2023-03-30 First Wave Bio, Inc. Deuterated niclosamide
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US20230190684A1 (en) 2020-03-16 2023-06-22 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound
JP7490813B2 (ja) * 2020-04-22 2024-05-27 ユンジン ファーム．カンパニー、リミテッド 安全性と安定性が改善されたピルフェニドンを含む腸溶性製剤およびその製造方法
IT202000011050A1 (it) * 2020-05-14 2021-11-14 Mogon Pharmaceuticals Sagl Composizioni orali solide comprendenti matrici monolitiche composite per la somministrazione cronotropica nel tratto gastroenterico di ingredienti attivi
CN115192535B (zh) * 2022-06-23 2023-08-29 广东逸舒制药股份有限公司 一种氨糖美辛肠溶片及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2764590A (en) * 1952-03-17 1956-09-25 Thomae Gmbh Dr K Certain 4, 4'-disubstituted-diphenylpyridyl methanes and process
DE1204363B (de) * 1963-09-10 1965-11-04 Hoffmann La Roche Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt
LU72439A1 (de) * 1975-05-09 1977-02-09
JPS53133625A (en) * 1977-04-25 1978-11-21 Shin Etsu Chem Co Ltd Manufacturing of pharmaceutical coated with enteric film
IT1115596B (it) * 1978-03-13 1986-02-03 Bayer Italia Spa Metodo per la preparazione di microgranuli gastoresistenti ed enterosolubili di sostanze farmaceutiche,in particolare di sostanze proteiche e microgranuli preparati con detto metodo
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
JPS5799521A (en) * 1980-12-11 1982-06-21 Eisai Co Ltd Solid composition containing bisacodyl
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
JPS59139317A (ja) * 1983-01-31 1984-08-10 Teisan Seiyaku Kk 持続性のニフエジピン製剤
JPS59193816A (ja) * 1983-04-19 1984-11-02 Morishita Jintan Kk 腸溶性軟カプセルの製造法
FR2556965B1 (fr) * 1983-12-21 1986-08-22 Rhone Poulenc Sante Nouvelle forme galenique du ketoprofene a liberation controlee
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS61221117A (ja) * 1985-03-26 1986-10-01 Fujisawa Pharmaceut Co Ltd 腸溶性硬カプセル剤
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4822629A (en) * 1986-12-12 1989-04-18 Norwich Eaton Pharmaceuticals, Inc. Azumolene dosage form
US4816259A (en) * 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
JPS63258815A (ja) * 1987-04-16 1988-10-26 Kiyuushin Seiyaku Kk ビサコジル含有固形組成物
JP2782691B2 (ja) * 1987-09-29 1998-08-06 ワーナー−ランバート・コンパニー 腸溶製剤の安定化
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
JPH089536B2 (ja) * 1987-10-30 1996-01-31 日清製粉株式会社 腸溶性カプセルの製造方法
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) * 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JPH064531B2 (ja) * 1990-06-04 1994-01-19 アイセロ化学株式会社 大腸崩壊性硬質カプセル
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5330759A (en) * 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
SK104895A3 (en) * 1993-02-26 1996-06-05 Procter & Gamble Pharmaceutical composition and its use
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
DE4314799C2 (de) * 1993-05-05 1995-04-13 Fein C & E Elektrowerkzeug
NZ283160A (en) * 1994-05-06 1998-07-28 Pfizer Azithromycin in a controlled release dosage form for treating microbiol infections
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system

Also Published As

Publication number Publication date
CN1233170A (zh) 1999-10-27
DE69719774D1 (de) 2003-04-17
EP0932396A1 (de) 1999-08-04
EP0932396B1 (de) 2003-03-12
DE69719774T2 (de) 2003-08-21
JP2001502333A (ja) 2001-02-20
CA2268175C (en) 2002-04-23
CN1101675C (zh) 2003-02-19
WO1998016206A1 (en) 1998-04-23
CA2268175A1 (en) 1998-04-23
US5914132A (en) 1999-06-22
BR9712292A (pt) 1999-08-31
JP4276299B2 (ja) 2009-06-10

Similar Documents

Publication Publication Date Title
ATE234079T1 (de) Pharmazeutische dosierungsform mit mehrfachen enterischen polymer-überzügenzur abgabe im kolon
DE69619668D1 (de) Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon
CA2268868A1 (en) Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
DE69630375D1 (de) Pharmazeutische dosierungsform zur freisetzung im colon
AU713722B2 (en) Gastrointestinal drug delivery system
US6531152B1 (en) Immediate release gastrointestinal drug delivery system
EP1021171B1 (de) Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
CA2446712C (en) System for osmotic delivery of pharmaceutically active agents
DK0754452T3 (da) Farmaceutisk præparat i form af en overtrukket kapsel, der frigives i den nedre del af fordøjelsessystemet
KR930700076A (ko) 항파킨슨제를 전달하기 위한 제형
DE60237372D1 (de) Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
ATE389389T1 (de) Mehrfach beschichete pharmazeutische dosierungsform
ATE211649T1 (de) Dosisform mit gesteuerter freigabe für kalium
FI98343B (fi) Peroraalinen formulaatio
PT98374A (pt) Dispositivo osmotico para administracao sistemica de nicotina e processo nele baseado
FI108400B (fi) Annosteluvõline ja menetelmõ sen valmistamiseksi
CA2271569A1 (en) Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
CA2271560A1 (en) Pharmaceutical dosage form for colonic delivery
NO992350L (no) Farmas°ytisk doseringsform med multiple enteriske polymerbelegg for avlevering i tykktarmen
NO992349L (no) Farmas°ytisk doseform for avlevering i tykktarmen
BR9612800A (pt) Forma de dosagem farmacêutica para distribuição colÈnica.
BR9612801A (pt) Forma de dosagem farmacêutica com múltiplos revestimentos de polìmeros entéricos para o fornecimento colÈnico.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties